Pharsight

News

Feb 27, 2024
Switzerland and India have made progress in their negotiations on a free trade agreement, with a focus on intellectual property protection. The Swiss pharmaceutical industry has argued for stronger patent protection to prevent Indian drug-makers from producing copycat generics, while India has resisted attempts by multinational drug-makers to strengthen patent protection. The outcome of the negotiations could have significant implications for affordable medicine access, as India is the largest producer of generics in the world and supplies around two-thirds of the world's antiretroviral drugs.
Feb 27, 2024
Roche Pharma India has launched Ocrevus (Ocrelizumab), a breakthrough drug for the treatment of multiple sclerosis (MS). Ocrevus is the first and only approved high efficacy therapy, with over 300,000 patients treated worldwide. It is the only monoclonal antibody drug approved for both relapsing-remitting and primary progressive forms of MS. Clinical data has shown that Ocrevus can significantly delay disability progression, with over 80% of people with RRMS and over 33% with PPMS showing no signs of disability. The drug is already available in over 100 countries.
Feb 27, 2024
Roche Pharma India has launched its breakthrough drug, Ocrevus (ocrelizumab), for the treatment of multiple sclerosis (MS) in India. Ocrevus is the only monoclonal antibody drug approved for the treatment of both RRMS and PPMS, showing significant impact on slowing disability progression. The drug has a streamlined administration and a commendable long-term safety record. It is the first and only approved therapy for both PPMS and RMS. Ocrevus is administered every six months, leading to high persistence and superior adherence to treatment. It is estimated that 300,000+ patients have been treated globally with Ocrevus.
Read more about | IMPACT |
Feb 27, 2024
Roche Pharma India has launched Ocrevus (ocrelizumab) in India for the treatment of multiple sclerosis (MS). Ocrevus is the only monoclonal antibody drug approved for both relapsing forms of MS and primary progressive MS, and has demonstrated significant efficacy and safety. The drug is administered twice a year, making it convenient for patients. Roche Pharma India's neurology portfolio aims to address the unmet needs of MS patients in India.
Feb 27, 2024
Hikma Pharmaceuticals' US unit has filed for pre-patent expiry approval from the US Food and Drug Administration (FDA) to launch a generic version of Merck's Bridion injection. Bridion, a key muscle relaxant reversal agent used in surgery, is currently under patent protection. If approved, the entry of a generic version could potentially reduce costs for healthcare providers and patients. However, Merck has hinted at potential legal challenges to protect their intellectual property. This clash could set important precedents for future pharmaceutical patent disputes, highlighting the ongoing tension between innovation and accessibility in healthcare.
Read more about | HIKMA | MERCK | BRIDION|
Feb 26, 2024
Krystal Biotech's Vyjuvek, a topical gene therapy for the rare skin disease dystrophic epidermolysis bullosa (DEB), has generated $50.7 million in product revenues in its first six months on the market. Vyjuvek, the first topical gene therapy to be approved by the FDA, is a genetically modified herpes simplex virus that delivers copies of the COL7A1 gene when applied to DEB wounds. The company is also working on an eye-drop formulation of Vyjuvek to treat ocular DEB complications, and plans to launch in Europe and Japan by 2025.
Feb 26, 2024
TL1A inhibitors may revolutionize the treatment of immune-mediated diseases such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Two monoclonal antibodies targeting TL1A have recently attracted significant attention, resulting in major acquisitions and collaborations in the biopharma industry. These inhibitors show promise in breaking the efficacy ceiling seen with current treatment options and offer the potential for higher remission rates and durability of response. Diagnostic tools that use genetic testing may also help identify patients who are more likely to benefit from TL1A inhibitors. Additionally, TL1A inhibitors may have applications in reversing fibrosis and scarring, offering novel benefits in other autoimmune diseases.
Feb 26, 2024
Zealand Pharma's stock surged by over 34% after announcing positive results from a clinical trial for its liver disease and weight loss drug, survodutide. The drug, being developed in partnership with Boehringer Ingelheim, demonstrated significant improvements in treating a liver condition called MASH in 83% of patients. Survodutide is currently undergoing phase three trials for obesity treatment and previous trials showed promising weight loss results. With the demand for weight loss drugs on the rise, Zealand Pharma is competing with companies like Novo Nordisk and Eli Lilly in this lucrative market.
Feb 26, 2024
A compounding pharmacy scam in Australia has been targeting general practices and patients, with fake products being shilled to those seeking semaglutide, a drug in shortage worldwide. Pharmacist Adam Reinhard says his business's name and reputation have been co-opted by the scammers.
Read more about | SEMAGLUTIDE|
Feb 26, 2024
GSK's drug Gepotidacin has shown success in treating gonorrhoea, according to trial data. The clinical trial found that the antibiotic was just as effective as the current combination of drugs used to treat the infection. Gepotidacin, discovered by scientists at GSK, offers an alternative for patients who may have allergies or intolerances to the current antibiotics. The drug is also expected to have blockbuster potential, potentially earning over £1 billion in annual sales.